RSV vaccination programs recommended for seniors: national immunization committee
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$1 per week for 24 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $4.00 plus GST every four weeks. After 24 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.99/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19.95 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 12/07/2024 (619 days ago), so information in it may no longer be current.
The National Advisory Committee on Immunization is strongly recommending a vaccination program against respiratory syncytial virus for older seniors and those living in long-term care homes.
The committee says vaccination against RSV should be provided to seniors aged 75 and older.
It says residents of long-term care or other chronic care facilities should be offered RSV immunization earlier, starting at age 60.
The immunization committee says other adults between 60 and 74 years old should talk to their care provider about whether to get the shot.
There are two RSV vaccines available in Canada: Arexvy, manufactured by GSK, and Abrysvo, made by Pfizer.
The Public Health Agency of Canada says older adults, as well as infants, are at higher risk for severe illness from the virus.
RSV causes cold-like symptoms that are usually mild but can sometimes cause severe infection of the lower respiratory tract that requires hospitalization.
This report by The Canadian Press was first published July 12, 2024.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.